EX-99.1
2
simulations_8kex99-1.htm
PRESS RELEASE, DATED JUNE 20, 2006
Unassociated Document
Exhibit
99.1
Simulations
Plus
Integrating
Science and Software
For
Further Information:
Simulations
Plus, Inc.
42505
10th
Street
West
Lancaster,
CA 93534-7059
CONTACT
:
Investor
Relations
Ms.
Renée
Bouché
Simulations
Plus, Inc.
661.723.7723
info@simulations-plus.com
For
Immediate Release:
June
20,
2006
Simulations
Plus Reports Preliminary Results for Third Fiscal Quarter
Company
CEO to Present at Wall Street Reporter Small-Cap Discovery
Conference
LANCASTER,
CA, June 20, 2006 -
Simulations
Plus, Inc. (AMEX: SLP), a leading provider of simulation and modeling software
for pharmaceutical discovery and development,
today
reported preliminary financial results for the third fiscal quarter of its
2006
fiscal year ended May 31, 2006, and announced that the company's CEO will be
presenting at the Wall Street Reporter Small-Cap Discovery Conference in New
York on Wednesday, June 21, 2006.
Ms.
Momoko Beran, chief financial officer of Simulations Plus, stated: "Consolidated
revenues for the third quarter were $1,789,000, an increase of 25.6% from
$1,424,000 in the third quarter of fiscal year 2005. This is not only a new
record for third quarter revenues, but is a record for all quarters when
multi-year licenses are recognized ratably (year-by-year rather than up front).
Revenues from pharmaceutical software and services were $1,097,000, an increase
of 65.7% from $662,000 in the third quarter of fiscal year 2005. Revenues for
our Words+ subsidiary decreased 9.2% to $692,000 from $762,000 in the third
quarter of fiscal year 2005. Final earnings will not be known until we complete
the auditors' review and tax calculations, but we estimate at this time that
earnings for the quarter should be in the range of $0.07-0.11 per
share.
"For
the
first nine months, revenues were $4,089,000, an increase of 16.1% over
$3,523,000 for the first nine months of fiscal year 2005. Sales of
pharmaceutical software licenses and services in the first nine months were
$2,179,000, an increase of 36.5% over $1,596,000 in the first nine months of
fiscal year 2005. Words+ sales were $1,910,000, a decrease of 0.8% from
$1,926,000 in the previous fiscal year. Again, earnings will not be known for
a
few more weeks, but we estimate that earnings for the first nine months will
be
in the range of $0.08-0.12 per share. Cash flow is good and our cash and
equivalents at the end of the third quarter exceeded $1 million. The Company
remains debt-free".
Walt
Woltosz, chairman and chief executive officer of Simulations Plus, noted:
"Although it is no longer our practice to provide preliminary results, our
decision to do so at this time was due to our participation in Wall Street
Reporter's Small-Cap Discovery Conference and, clearly, we're very pleased with
these preliminary results. In my travels I have been receiving very positive
feedback from both large and small customers, with a number of them indicating
they plan to increase their number of software licenses and obtain training
for
additional scientists. The pharmaceutical industry seems to be adopting
simulation and modeling software at an accelerating rate. The recent move by
Novartis in setting up a separate Simulation and Modeling Department headed
by a
vice president demonstrates the growing recognition of higher level industry
management of the importance of these technologies".
-more-
About
Simulations Plus, Inc.
Simulations
Plus, Inc. is a premier developer of groundbreaking drug discovery and
development simulation software, which is licensed to and used in the conduct
of
drug research by major pharmaceutical and biotechnology companies worldwide.
We
have two other businesses that are based on our proprietary technologies: a
wholly owned subsidiary, Words+, Inc., which provides assistive technologies
to
persons with disabilities; and an educational software series for science
students in middle and high schools known as FutureLab™.
For
more information, visit our Web site at www.simulations-plus.com.
Safe
Harbor Statement Under the Private Securities Litigation Reform Act of
1995
- With
the exception of historical information, the matters discussed in this press
release are forward-looking statements that involve a number of risks and
uncertainties. Our actual future results could differ significantly from those
statements. Factors that could cause or contribute to such differences include,
but are not limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing software by
our
customers, the general economics of the pharmaceutical industry, our ability
to
finance growth, our ability to continue to attract and retain highly qualified
technical staff, and a sustainable market. Further information on our risk
factors is contained in our quarterly and annual reports as filed with the
Securities and Exchange Commission.
###

EX - 99 . 1 2 simulations _ 8kex99 - 1 . htm PRESS RELEASE , DATED JUNE 20 , 2006 Un associated Document Exhibit 99 . 1 Simulations Plus Integrating Science and Software For Further Information : Simulations Plus , Inc . 42505 10th Street West Lancaster , CA 93534 - 7059 CONTACT : Investor Relations Ms . Renée Bouché Simulations Plus , Inc . 661 . 723 . 7723 info@simulations-plus.com For Immediate Release : June 20 , 2006 Simulations Plus Reports Preliminary Results for Third Fiscal Quarter Company CEO to Present at Wall Street Reporter Small - Cap Discovery Conference LANCASTER , CA , June 20 , 2006 - Simulations Plus , Inc . ( AMEX : SLP ) , a leading provider of simulation and modeling software for pharmaceutical discovery and development , today reported preliminary financial results for the third fiscal quarter of its 2006 fiscal year ended May 31 , 2006 , and announced that the company 's CEO will be presenting at the Wall Street Reporter Small - Cap Discovery Conference in New York on Wednesday , June 21 , 2006 . Ms . Momoko Beran , chief financial officer of Simulations Plus , stated : " Consolidated revenues for the third quarter were $ 1,789,000 , an increase of 25 . 6 % from $ 1,424,000 in the third quarter of fiscal year 2005 . This is not only a new record for third quarter revenues , but is a record for all quarters when multi - year licenses are recognized ratably ( year - by - year rather than up front ) . Revenues from pharmaceutical software and services were $ 1,097,000 , an increase of 65 . 7 % from $ 662,000 in the third quarter of fiscal year 2005 . Revenues for our Words + subsidiary decreased 9 . 2 % to $ 692,000 from $ 762,000 in the third quarter of fiscal year 2005 . Final earnings will not be known until we complete the auditors ' review and tax calculations , but we estimate at this time that earnings for the quarter should be in the range of $ 0.07 - 0 . 11 per share . " For the first nine months , revenues were $ 4,089,000 , an increase of 16 . 1 % over $ 3,523,000 for the first nine months of fiscal year 2005 . Sales of pharmaceutical software licenses and services in the first nine months were $ 2,179,000 , an increase of 36 . 5 % over $ 1,596,000 in the first nine months of fiscal year 2005 . Words + sales were $ 1,910,000 , a decrease of 0 . 8 % from $ 1,926,000 in the previous fiscal year . Again , earnings will not be known for a few more weeks , but we estimate that earnings for the first nine months will be in the range of $ 0.08 - 0 . 12 per share . Cash flow is good and our cash and equivalents at the end of the third quarter exceeded $ 1 million . The Company remains debt - free " . Walt Woltosz , chairman and chief executive officer of Simulations Plus , noted : " Although it is no longer our practice to provide preliminary results , our decision to do so at this time was due to our participation in Wall Street Reporter 's Small - Cap Discovery Conference and , clearly , we ' re very pleased with these preliminary results . In my travels I have been receiving very positive feedback from both large and small customers , with a number of them indicating they plan to increase their number of software licenses and obtain training for additional scientists . The pharmaceutical industry seems to be adopting simulation and modeling software at an accelerating rate . The recent move by Novartis in setting up a separate Simulation and Modeling Department headed by a vice president demonstrates the growing recognition of higher level industry management of the importance of these technologies " . - more - About Simulations Plus , Inc . Simulations Plus , Inc . is a premier developer of groundbreaking drug discovery and development simulation software , which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide . We have two other businesses that are based on our proprietary technologies : a wholly owned subsidiary , Words + , Inc . , which provides assistive technologies to persons with disabilities ; and an educational software series for science students in middle and high schools known as FutureLab ™ . For more information , visit our Web site at www.simulations-plus.com . Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 - With the exception of historical information , the matters discussed in this press release are forward - looking statements that involve a number of risks and uncertainties . Our actual future results could differ significantly from those statements . Factors that could cause or contribute to such differences include , but are not limited to : our ability to maintain our competitive advantages , acceptance of new software and improved versions of our existing software by our customers , the general economics of the pharmaceutical industry , our ability to finance growth , our ability to continue to attract and retain highly qualified technical staff , and a sustainable market . Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission . # # #